Brief: NGM Bio Presents Updated Preliminary Findings From The Ongoing Phase 1B Dose Escalation Trial Of NGM120
13/09/2022 22:36
Sept 13 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO PRESENTS UPDATED PRELIMINARY FINDINGS FROM THE
ONGOING
PHASE 1B DOSE ESCALATION TRIAL OF NGM120 IN COMBINATION WITH
GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH METASTATIC
PANCREATIC CANCER AT AACR SPECIAL CONFERENCE: PANCREATIC CANCER
* NGM BIOPHARMACEUTICALS INC- NGM120 HAS BEEN WELL TOLERATED
TO
DATE IN PATIENTS IN PHASE 1B COMBINATION COHORT WITH NO
DOSE-LIMITING TOXICITIES
Source text for Eikon: ID:nGNX24glZk
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors